16-1210666-G-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_021098.3(CACNA1H):c.4038+15G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000756 in 1,598,618 control chromosomes in the GnomAD database, including 5 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0038 ( 3 hom., cov: 33)
Exomes 𝑓: 0.00043 ( 2 hom. )
Consequence
CACNA1H
NM_021098.3 intron
NM_021098.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.680
Publications
0 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 16-1210666-G-T is Benign according to our data. Variant chr16-1210666-G-T is described in ClinVar as [Likely_benign]. Clinvar id is 445468.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00382 (582/152270) while in subpopulation AFR AF = 0.012 (499/41560). AF 95% confidence interval is 0.0111. There are 3 homozygotes in GnomAd4. There are 272 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High AC in GnomAd4 at 582 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.4038+15G>T | intron_variant | Intron 20 of 34 | 1 | NM_021098.3 | ENSP00000334198.7 | |||
CACNA1H | ENST00000569107.6 | c.4038+15G>T | intron_variant | Intron 20 of 33 | 1 | ENSP00000454990.2 | ||||
CACNA1H | ENST00000711493.1 | c.4038+15G>T | intron_variant | Intron 20 of 33 | ENSP00000518778.1 | |||||
CACNA1H | ENST00000565831.7 | c.4038+15G>T | intron_variant | Intron 20 of 33 | 1 | ENSP00000455840.1 | ||||
CACNA1H | ENST00000711450.1 | c.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518762.1 | |||||
CACNA1H | ENST00000564231.6 | c.4038+15G>T | intron_variant | Intron 20 of 34 | 1 | ENSP00000457555.2 | ||||
CACNA1H | ENST00000638323.1 | c.3999+15G>T | intron_variant | Intron 20 of 34 | 5 | ENSP00000492267.1 | ||||
CACNA1H | ENST00000562079.6 | c.4038+15G>T | intron_variant | Intron 20 of 33 | 1 | ENSP00000454581.2 | ||||
CACNA1H | ENST00000711438.1 | c.3999+15G>T | intron_variant | Intron 20 of 33 | ENSP00000518754.1 | |||||
CACNA1H | ENST00000711482.1 | c.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518771.1 | |||||
CACNA1H | ENST00000711485.1 | c.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518774.1 | |||||
CACNA1H | ENST00000711455.1 | c.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518768.1 | |||||
CACNA1H | ENST00000711483.1 | c.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518772.1 | |||||
CACNA1H | ENST00000711456.1 | c.4038+15G>T | intron_variant | Intron 20 of 33 | ENSP00000518769.1 | |||||
CACNA1H | ENST00000621827.2 | n.4038+15G>T | intron_variant | Intron 20 of 36 | 6 | ENSP00000518766.1 | ||||
CACNA1H | ENST00000637236.3 | n.*8+15G>T | intron_variant | Intron 20 of 33 | 5 | ENSP00000492650.2 | ||||
CACNA1H | ENST00000639478.1 | n.4038+15G>T | intron_variant | Intron 20 of 34 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.*1951+15G>T | intron_variant | Intron 20 of 34 | 5 | ENSP00000491488.1 | ||||
CACNA1H | ENST00000711442.1 | n.*3485+15G>T | intron_variant | Intron 19 of 33 | ENSP00000518758.1 | |||||
CACNA1H | ENST00000711448.1 | n.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518760.1 | |||||
CACNA1H | ENST00000711449.1 | n.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518761.1 | |||||
CACNA1H | ENST00000711451.1 | n.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518763.1 | |||||
CACNA1H | ENST00000711452.1 | n.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518764.1 | |||||
CACNA1H | ENST00000711453.1 | n.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518765.1 | |||||
CACNA1H | ENST00000711484.1 | n.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518773.1 | |||||
CACNA1H | ENST00000711486.1 | n.4038+15G>T | intron_variant | Intron 20 of 36 | ENSP00000518775.1 | |||||
CACNA1H | ENST00000711487.1 | n.4038+15G>T | intron_variant | Intron 20 of 35 | ENSP00000518776.1 | |||||
CACNA1H | ENST00000711488.1 | n.4038+15G>T | intron_variant | Intron 20 of 34 | ENSP00000518777.1 |
Frequencies
GnomAD3 genomes AF: 0.00383 AC: 582AN: 152152Hom.: 3 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
582
AN:
152152
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000992 AC: 230AN: 231952 AF XY: 0.000760 show subpopulations
GnomAD2 exomes
AF:
AC:
230
AN:
231952
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000434 AC: 627AN: 1446348Hom.: 2 Cov.: 38 AF XY: 0.000393 AC XY: 283AN XY: 719696 show subpopulations
GnomAD4 exome
AF:
AC:
627
AN:
1446348
Hom.:
Cov.:
38
AF XY:
AC XY:
283
AN XY:
719696
show subpopulations
African (AFR)
AF:
AC:
431
AN:
33404
American (AMR)
AF:
AC:
41
AN:
44374
Ashkenazi Jewish (ASJ)
AF:
AC:
62
AN:
26060
East Asian (EAS)
AF:
AC:
0
AN:
39560
South Asian (SAS)
AF:
AC:
1
AN:
85874
European-Finnish (FIN)
AF:
AC:
0
AN:
40910
Middle Eastern (MID)
AF:
AC:
4
AN:
5756
European-Non Finnish (NFE)
AF:
AC:
28
AN:
1110280
Other (OTH)
AF:
AC:
60
AN:
60130
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.472
Heterozygous variant carriers
0
38
75
113
150
188
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.00382 AC: 582AN: 152270Hom.: 3 Cov.: 33 AF XY: 0.00365 AC XY: 272AN XY: 74456 show subpopulations
GnomAD4 genome
AF:
AC:
582
AN:
152270
Hom.:
Cov.:
33
AF XY:
AC XY:
272
AN XY:
74456
show subpopulations
African (AFR)
AF:
AC:
499
AN:
41560
American (AMR)
AF:
AC:
32
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
AC:
12
AN:
3470
East Asian (EAS)
AF:
AC:
0
AN:
5162
South Asian (SAS)
AF:
AC:
0
AN:
4822
European-Finnish (FIN)
AF:
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
3
AN:
68006
Other (OTH)
AF:
AC:
5
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.494
Heterozygous variant carriers
0
30
61
91
122
152
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Epilepsy, childhood absence, susceptibility to, 6;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jul 27, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided Benign:1
Aug 31, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.